About Katie

Katie is an intellectual property lawyer with expertise across sectors including medtech, pharmaceuticals, engineering and fast-moving consumer goods. With a degree in Science (majoring in Pharmacology), her practice has a particular focus on matters relating to highly complex technical subject matter.

Katie has advised various multinational clients on IP commercialisation, transactions, enforcement and freedom to operate. She has acted in a number of global patent disputes, involving proceedings before the Federal Court of Australia, High Court of Australia, UK High Court and Court of Appeal and the European Patent Office.

Prior to joining Maddocks, Katie spent nine years working at a leading global firm in Melbourne and London.

Experience

• Life sciences acquisition

  Advising Acacia Research Corporation on IP aspects of its acquisition of up to 19 public and private life sciences companies for a total consideration of over £220 million.

• Patent revocation

  Advising CSL Limited in a patent revocation action as part of its broader European strategy in relation to its C1-esterase inhibitor therapy, HAEGARDA®.

• FMCG transaction

  Advising a major multinational FMCG company on trade mark, copyright and confidential information issues as part of a high-value transaction.

• Multi-jurisdictional patent litigation

  Advising Foundation Medicine, Inc., a subsidiary of the Roche group, on a multi-jurisdictional patent dispute concerning its next generation sequencing-based companion diagnostic for the analysis of tumor alterations, FoundationOne®Liquid CDx.

  Advising Ariosa on a multi-jurisdictional multi-patent dispute concerning its Harmony® non-invasive prenatal genetic test, including a defence of patent infringement proceedings in the UK Patents Court and Court of Appeal.

• IP commercialisation

  Advising various leading pharmaceutical companies on patent licence and commercialisation issues, including drafting and negotiation of agreements.

• Enforcement

  Advising Takeda on pan-European enforcement strategy in relation to its multiple myeloma drug Velcade®.